Hideho Okada

List of Publications by Year
in descending order

132 papers	11,217 citations	34105 52 h-index	32842 100 g-index
138 all docs	138 docs citations	138 times ranked	14264 citing authors

#	Article	IF	Citations
1	Novel EGFRvIII-CAR transgenic mice for rigorous preclinical studies in syngeneic mice. Neuro-Oncology, 2022, 24, 259-272.	1.2	6
2	Immunomodulatory roles of myeloid cells in gliomas. , 2022, , 109-125.		0
3	The current landscape of immunotherapy for pediatric brain tumors. Nature Cancer, 2022, 3, 11-24.	13.2	21
4	Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas. Journal of Clinical Investigation, 2022, 132, .	8.2	32
5	The immunology of low-grade gliomas. Neurosurgical Focus, 2022, 52, E2.	2.3	20
6	Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma. , 2022, 10, e004644.		14
7	The future of cancer immunotherapy for brain tumors: a collaborative workshop. Journal of Translational Medicine, 2022, 20, .	4.4	7
8	IMMU-14. SynNotch chimeric antigen receptor (CAR) T-cells as a potential treatment for diffuse intrinsic pontine glioma (DIPG)/diffuse midline glioma (DMG). Neuro-Oncology, 2022, 24, i84-i84.	1.2	0
9	Considerations when treating high-grade pediatric glioma patients with immunotherapy. Expert Review of Neurotherapeutics, 2021, 21, 205-219.	2.8	5
10	Current Advances in Immunotherapy for Glioblastoma. Current Oncology Reports, 2021, 23, 21.	4.0	26
11	SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Science Translational Medicine, 2021, 13, .	12.4	215
12	Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma. , 2021, 9, e002181.		42
13	IFN-Î3- and IL-17-producing CD8⁺ T (Tc17-1) cells in combination with poly-ICLC and peptide vaccine exhibit antiglioma activity. , 2021, 9, e002426.		8
14	The evolution of alternative splicing in glioblastoma under therapy. Genome Biology, 2021, 22, 48.	8.8	23
15	Assessing Oximetry Response to Chimeric Antigen Receptor T-cell Therapy against Glioma with 19F MRI in a Murine Model. Radiology Imaging Cancer, 2021, 3, e200062.	1.6	7
16	Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade. JCI Insight, 2021, 6, .	5.0	46
17	Unique challenges for glioblastoma immunotherapyâ€"discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. Neuro-Oncology, 2021, 23, 356-375.	1.2	59
18	Cell penetrating peptide functionalized perfluorocarbon nanoemulsions for targeted cell labeling and enhanced fluorineâ€19 MRI detection. Magnetic Resonance in Medicine, 2020, 83, 974-987.	3.0	40

#	Article	IF	Citations
19	Treatment-induced lesions in newly diagnosed glioblastoma patients undergoing chemoradiotherapy and heat-shock protein vaccine therapy. Journal of Neuro-Oncology, 2020, 146, 71-78.	2.9	5
20	The current state of immunotherapy for primary and secondary brain tumors: similarities and differences. Japanese Journal of Clinical Oncology, 2020, 50, 1231-1245.	1.3	13
21	The Great Debate at â€˜Immunotherapy Bridgeâ€™, Naples, December 5, 2019. , 2020, 8, e000921.		3
22	T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment. Journal of Neuro-Oncology, 2020, 147, 281-295.	2.9	32
23	Introduction to immunotherapy for brain tumor patients: challenges and future perspectives. Neuro-Oncology Practice, 2020, 7, 465-476.	1.6	10
24	Tumor antigens in glioma. Seminars in Immunology, 2020, 47, 101385.	5.6	34
25	Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity. Nature Communications, 2020, 11, 524.	12.8	29
26	Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma. Journal of Clinical Investigation, 2020, 130, 6325-6337.	8.2	70
27	THER-05. GENETICALLY STABLE POLIOVIRUS VECTOR CARRYING H3.3K27M ANTIGEN FOR TREATMENT OF DIFFUSE MIDLINE GLIOMA BY INTRAMUSCULAR INJECTION. Neuro-Oncology, 2020, 22, iii472-iii472.	1.2	0
28	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. Molecular and Cellular Proteomics, 2019, 18, 1255-1268.	3.8	45
29	IMMU-18. TARGETING H3.3 K27M MUTATION AS A SHARED NEOANTIGEN IN HLA-A*0201+ PATIENTS WITH DIFFUSE MIDLINE GLIOMAS â€“ DEVELOPMENT OF A NOVEL MASS CYTOMETRY-BASED MONITORING OF VACCINE-REACTIVE, EPITOPE-SPECIFIC CD8+ T CELL RESPONSES. Neuro-Oncology, 2019, 21, ii96-ii96.	1.2	1
30	The immune suppressive microenvironment of human gliomas depends on the accumulation of bone marrow-derived macrophages in the center of the lesion. , 2019, 7, 58.		109
31	Immunotherapy for High-Grade Gliomas: A Clinical Update and Practical Considerations for Neurosurgeons. World Neurosurgery, 2019, 124, 397-409.	1.3	19
32	RDNA-09. RADIATION PRIMES SB28 GLIOBLASTOMA FOR RESPONSE TO TGFÎ² AND PD-L1 NEUTRALIZING ANTIBODIES. Neuro-Oncology, 2019, 21, vi208-vi208.	1.2	2
33	PDCT-17 (LTBK-11). PNOC007: H3.3K27M SPECIFIC PEPTIDE VACCINE COMBINED WITH POLY-ICLC FOR THE TREATMENT OF NEWLY DIAGNOSED HLA-A2+ H3.3K27M MIDLINE GLIOMAS. Neuro-Oncology, 2019, 21, vi284-vi285.	1.2	1
34	IMMU-11. SPATIOTEMPORAL IMMUNOGENOMIC ANALYSIS OF THE T-CELL REPERTOIRE IN IDH-MUTANT LOWER GRADE GLIOMAS. Neuro-Oncology, 2019, 21, vi121-vi121.	1.2	0
35	IMMU-38. CRISPR BASED GENOME EDITING OF HUMAN T CELLS TO TARGET H3.3K27M MUTATION IN GLIOMAS. Neuro-Oncology, 2019, 21, vi127-vi127.	1.2	0
36	IMMU-45. CAR-T TREATMENT OF NOVEL MOUSE MODEL OF EGFRVIII+ GBM MIRRORS CLINICAL TRIAL OUTCOMES AND PROVIDES A SYNGENEIC PLATFORM FOR THE INVESTIGATION OF CAR-T MECHANISMS OF ACTION. Neuro-Oncology, 2019, 21, vi128-vi129.	1.2	0

#	Article	IF	Citations
37	IMMU-21. SEQUENTIAL TWO-RECEPTOR PRIMING CAR SYSTEM TO OVERCOME HETEROGENEOUS ANTIGEN EXPRESSION. Neuro-Oncology, 2019, 21, vi123-vi123.	1.2	0
38	IMMU-30. UTILIZING A NOVEL MASS CYTOMETRY-BASED IMMUNOMONITORING PLATFORM FOR THE CHARACTERIZATION OF VACCINE-REACTIVE, EPITOPE-SPECIFIC CD8+ T-CELLS IN HLA-A*0201+ PATIENTS WITH K27M+ DIFFUSE MIDLINE GLIOMAS. Neuro-Oncology, 2019, 21, vi125-vi125.	1.2	0
39	Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature, 2019, 565, 240-245.	27.8	637
40	Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma. OncoImmunology, 2018, 7, e1391972.	4.6	42
41	Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy. Journal of Experimental Medicine, 2018, 215, 141-157.	8.5	186
42	IMMU-57. SEQUENTIAL TWO-RECEPTOR PRIMING CAR SYSTEM TO OVERCOME HETEROGENEOUS ANTIGEN EXPRESSION. Neuro-Oncology, 2018, 20, vi134-vi134.	1.2	0
43	Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models. OncoImmunology, 2018, 7, e1501137.	4.6	120
44	Immunotherapy Response Assessment in Neuro-Oncology (iRANO). , 2018, , 761-766.		1
45	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. Molecular and Cellular Proteomics, 2018, 17, 2132-2145.	3.8	41
46	Immunotherapy of Primary Brain Tumors: Facts and Hopes. Clinical Cancer Research, 2018, 24, 5198-5205.	7.0	66
47	Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy. Frontiers in Immunology, 2018, 9, 3062.	4.8	49
48	Peptide vaccine immunotherapy biomarkers and response patterns in pediatric gliomas. JCI Insight, 2018, 3, .	5.0	21
49	Is the immune response a friend or foe for viral therapy of glioma?. Neuro-Oncology, 2017, 19, 882-883.	1.2	2
50	A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Science Translational Medicine, 2017, 9, .	12.4	1,116
51	Neuroimaging of Peptide-based Vaccine Therapy in Pediatric Brain Tumors. Neuroimaging Clinics of North America, 2017, 27, 155-166.	1.0	8
52	Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment. Genome Biology, 2017, 18, 234.	8.8	448
53	Fluorine-19 nuclear magnetic resonance of chimeric antigen receptor T cell biodistribution in murine cancer model. Scientific Reports, 2017, 7, 17748.	3.3	29
54	IMMU-52. SELECTION OF GLIOMA T-CELL THERAPY TARGETS BASED ON THE ANALYSIS OF TUMOR IMMUNOPEPTIDOME AND EXPRESSION PROFILES. Neuro-Oncology, 2017, 19, vi124-vi124.	1.2	0

#	Article	IF	Citations
55	ATIM-11. PILOT STUDY OF TUMOR LYSATE VACCINE AND IMIQUIMOD IN ADULTS WITH WHO GRADE II GLIOMAS. Neuro-Oncology, 2017, 19, vi28-vi28.	1.2	0
56	IMMU-42. ONO-AE3-208 PROMOTES ANTI-TUMOR IMMUNE ACTIVITY AND SURVIVAL IN GLIOMA MODELS. Neuro-Oncology, 2017, 19, vi122-vi122.	1.2	0
57	Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. Journal of Clinical Investigation, 2017, 127, 1425-1437.	8.2	334
58	IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression. Neuro-Oncology, 2016, 18, 1402-1412.	1.2	126
59	Detection of inflammatory cell function using 13C magnetic resonance spectroscopy of hyperpolarized [6-13C]-arginine. Scientific Reports, 2016, 6, 31397.	3.3	24
60	Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study. Journal of Neuro-Oncology, 2016, 130, 517-527.	2.9	49
61	Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma. Journal of Neuro-Oncology, 2016, 130, 543-552.	2.9	90
62	Cellular immunotherapy for malignant gliomas. Expert Opinion on Biological Therapy, 2016, 16, 1265-1275.	3.1	37
63	Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas. Neuro-Oncology, 2016, 18, 1157-1168.	1.2	69
64	Principles of immunology and its nuances in the central nervous system: Fig. 1.. Neuro-Oncology, 2015, 17, vii3-vii8.	1.2	28
65	Rational development and characterization of humanized antiâ€“EGFR variant III chimeric antigen receptor T cells for glioblastoma. Science Translational Medicine, 2015, 7, 275ra22.	12.4	369
66	Transgene-derived overexpression of miR-17-92 in CD8+ T-cells confers enhanced cytotoxic activity. Biochemical and Biophysical Research Communications, 2015, 458, 549-554.	2.1	26
67	Induction of Robust Type-I CD8+ T-cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC. Clinical Cancer Research, 2015, 21, 286-294.	7.0	92
68	Exosomes isolated from plasma of glioma patients enrolled in a vaccination trial reflect antitumor immune activity and might predict survival. OncoImmunology, 2015, 4, e1008347.	4.6	91
69	Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncology, The, 2015, 16, e534-e542.	10.7	582
70	Histamine deficiency promotes accumulation of immunosuppressive immature myeloid cells and growth of murine gliomas. OncoImmunology, 2015, 4, e1047581.	4.6	12
71	Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508.	1.8	395
72	STING Contributes to Antiglioma Immunity via Triggering Type I IFN Signals in the Tumor Microenvironment. Cancer Immunology Research, 2014, 2, 1199-1208.	3.4	185

#	Article	IF	Citations
73	Antigen-Specific Immune Responses and Clinical Outcome After Vaccination With Glioma-Associated Antigen Peptides and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Children With Newly Diagnosed Malignant Brainstem and Nonbrainstem Gliomas. Journal of Clinical Oncology, 2014, 32, 2050-2058.	1.6	167
74	Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells. Cancer Immunology, Immunotherapy, 2014, 63, 847-857.	4.2	82
75	GM-CSF Promotes the Immunosuppressive Activity of Glioma-Infiltrating Myeloid Cells through Interleukin-4 Receptor-Î±. Cancer Research, 2013, 73, 6413-6423.	0.9	169
76	Immune-Checkpoint Blockade and Active Immunotherapy for Glioma. Cancers, 2013, 5, 1379-1412.	3.7	33
77	Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts. , 2013, 1, 21.		85
78	Premetastatic soil and prevention of breast cancer brain metastasis. Neuro-Oncology, 2013, 15, 891-903.	1.2	76
79	LOH in the HLA Class I Region at 6p21 Is Associated with Shorter Survival in Newly Diagnosed Adult Glioblastoma. Clinical Cancer Research, 2013, 19, 1816-1826.	7.0	70
80	Vaccines Targeting Tumor Blood Vessel Antigens Promote CD8+ T Cell-Dependent Tumor Eradication or Dormancy in HLA-A2 Transgenic Mice. Journal of Immunology, 2012, 188, 1782-1788.	0.8	44
81	Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor Î±2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele. Cytotherapy, 2012, 14, 733-742.	0.7	56
82	Myeloid-derived Suppressor Cells (MDSCs) in Gliomas and Glioma-Development. Immunological Investigations, 2012, 41, 658-679.	2.0	56
83	Type17 T-cells in Central Nervous System Autoimmunity and Tumors. Journal of Clinical Immunology, 2012, 32, 802-808.	3.8	26
84	Expression of antigen processing and presenting molecules in brain metastasis of breast cancer. Cancer Immunology, Immunotherapy, 2012, 61, 789-801.	4.2	53
85	MicroRNAs and STAT interplay. Seminars in Cancer Biology, 2012, 22, 70-75.	9.6	94
86	Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy. Journal of Neuro-Oncology, 2011, 104, 83-92.	2.9	152
87	Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?. Immunologic Research, 2011, 50, 235-247.	2.9	28
88	COX-2 Blockade Suppresses Gliomagenesis by Inhibiting Myeloid-Derived Suppressor Cells. Cancer Research, 2011, 71, 2664-2674.	0.9	331
89	Do we need novel radiologic response criteria for brain tumor immunotherapy?. Expert Review of Neurotherapeutics, 2011, 11, 619-622.	2.8	22
90	Induction of CD8⁺T-Cell Responses Against Novel Gliomaâ€"Associated Antigen Peptides and Clinical Activity by Vaccinations With Î±-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma. Journal of Clinical Oncology, 2011, 29, 330-336.	1.6	519

#	Article	IF	Citations
91	Absence of Stat1 in donor CD4+ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice. Journal of Clinical Investigation, 2011, 121, 2554-2569.	8.2	72
92	Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-Î± and IFN-Î³ dependent manners. Cancer Immunology, Immunotherapy, 2010, 59, 1401-1409.	4.2	83
93	Role of Type 1 IFNs in Antiglioma Immunosurveillanceâ€"Using Mouse Studies to Guide Examination of Novel Prognostic Markers in Humans. Clinical Cancer Research, 2010, 16, 3409-3419.	7.0	80
94	miR-17-92 expression in differentiated T cells - implications for cancer immunotherapy. Journal of Translational Medicine, 2010, 8, 17.	4.4	67
95	MicroRNAs in immune regulationâ€"Opportunities for cancer immunotherapy. International Journal of Biochemistry and Cell Biology, 2010, 42, 1256-1261.	2.8	78
96	Polarized dendritic cells as cancer vaccines: Directing effector-type T cells to tumors. Seminars in Immunology, 2010, 22, 173-182.	5.6	62
97	Effective Immunotherapy against Murine Gliomas Using Type 1 Polarizing Dendritic Cellsâ€"Significant Roles of CXCL10. Cancer Research, 2009, 69, 1587-1595.	0.9	99
98	Systemic Inhibition of Transforming Growth Factor-Î² in Glioma-Bearing Mice Improves the Therapeutic Efficacy of Glioma-Associated Antigen Peptide Vaccines. Clinical Cancer Research, 2009, 15, 6551-6559.	7.0	106
99	Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 10746-10751.	7.1	161
100	Brain Tumor Immunotherapy with Typeâ€1 Polarizing Strategies. Annals of the New York Academy of Sciences, 2009, 1174, 18-23.	3.8	34
101	Immunotherapeutic Approaches for Glioma. Critical Reviews in Immunology, 2009, 29, 1-42.	0.5	132
102	Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas. Journal of Neuro-Oncology, 2008, 88, 245-250.	2.9	77
103	Inhibition of STAT3 Promotes the Efficacy of Adoptive Transfer Therapy Using Type-1 CTLs by Modulation of the Immunological Microenvironment in a Murine Intracranial Glioma. Journal of Immunology, 2008, 180, 2089-2098.	0.8	99
104	Stat6 Signaling Suppresses VLA-4 Expression by CD8+ T Cells and Limits Their Ability to Infiltrate Tumor Lesions In Vivo. Journal of Immunology, 2008, 181, 104-108.	0.8	28
105	Antigenic Profiling of Glioma Cells to Generate Allogeneic Vaccines or Dendritic Cellâ€"Based Therapeutics. Clinical Cancer Research, 2007, 13, 566-575.	7.0	146
106	Helper Function of Memory CD8+ T Cells: Heterologous CD8+ T Cells Support the Induction of Therapeutic Cancer Immunity. Cancer Research, 2007, 67, 10012-10018.	0.9	27
107	Preferential Expression of Very Late Antigen-4 on Type 1 CTL Cells Plays a Critical Role in Trafficking into Central Nervous System Tumors. Cancer Research, 2007, 67, 6451-6458.	0.9	60
108	Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. Journal of Translational Medicine, 2007, 5, 10.	4.4	161

#	Article	IF	Citations
109	Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. Journal of Translational Medicine, 2007, 5, 67.	4.4	112
110	Identification of Interleukin-13 Receptor Î±2 Peptide Analogues Capable of Inducing Improved Antiglioma CTL Responses. Cancer Research, 2006, 66, 5883-5891.	0.9	59
111	Adoptive Transfer of Type 1 CTL Mediates Effective Antiâ€"Central Nervous System Tumor Response: Critical Roles of IFN-Inducible Protein-10. Cancer Research, 2006, 66, 4478-4487.	0.9	84
112	Epidermal growth factor receptor-transfected bone marrow stromal cells exhibit enhanced migratory response and therapeutic potential against murine brain tumors. Cancer Gene Therapy, 2005, 12, 757-768.	4.6	98
113	IL-4-Transfected Tumor Cell Vaccines Activate Tumor-Infiltrating Dendritic Cells and Promote Type-1 Immunity. Journal of Immunology, 2005, 174, 7194-7201.	0.8	34
114	Delivery of Dendritic Cells Engineered to Secrete IFN-Î± into Central Nervous System Tumors Enhances the Efficacy of Peripheral Tumor Cell Vaccines: Dependence on Apoptotic Pathways. Journal of Immunology, 2005, 175, 2730-2740.	0.8	54
115	The Characterization of Tumor Apoptosis after Experimental Radiosurgery. Stereotactic and Functional Neurosurgery, 2005, 83, 17-24.	1.5	33
116	EphA2 as a Glioma-Associated Antigen: A Novel Target for Glioma Vaccines. Neoplasia, 2005, 7, 717-722.	5.3	126
117	Biologic Therapy for Brain Cancers - Based on Cellular and Immunobiology. Yonsei Medical Journal, 2004, 45, S68.	2.2	0
118	Cytokine gene therapy for malignant glioma. Expert Opinion on Biological Therapy, 2004, 4, 1609-1620.	3.1	53
119	Delivery of Interferon-Î± Transfected Dendritic Cells into Central Nervous System Tumors Enhances the Antitumor Efficacy of Peripheral Peptide-Based Vaccines. Cancer Research, 2004, 64, 5830-5838.	0.9	40
120	Title is missing!. Journal of Neuro-Oncology, 2003, 64, 13-20.	2.9	16
121	Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy. Journal of Neuro-Oncology, 2003, 64, 13-20.	2.9	74
122	Expression of a soluble transforming growth factor-Î² (TGFÎ²) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcomain vivo. Journal of Neuro-Oncology, 2003, 64, 63-69.	2.9	23
123	Effective induction of antiglioma cytotoxic T cells by coadministration of interferon-Î² gene vector and dendritic cells. Cancer Gene Therapy, 2003, 10, 549-558.	4.6	29
124	Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. Cancer Research, 2003, 63, 6378-86.	0.9	105
125	Gene Therapy and Biologic Therapy with Interleukin?4. Current Gene Therapy, 2002, 2, 437-450.	2.0	22
126	7-Hydroxystaurosporine-induced Apoptosis in 9L Glioma Cells Provides an Effective Antigen Source for Dendritic Cells and Yields a Potent Vaccine Strategy in an Intracranial Glioma Model. Neurosurgery, 2002, 50, 1327-1335.	1.1	26

#	Article	IF	Citations
127	Glioma-associated hyaluronan induces apoptosis in dendritic cells via inducible nitric oxide synthase: implications for the use of dendritic cells for therapy of gliomas. Cancer Research, 2002, 62, 2583-91.	0.9	58
128	Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. Clinical Cancer Research, 2002, 8, 2851-5.	7.0	99
129	Characterization and transduction of a retroviral vector encoding human interleukin-4 and herpes simplex virus-thymidine kinase for glioma tumor vaccine therapy. Cancer Gene Therapy, 2000, 7, 486-494.	4.6	13
130	Exploitation of immune mechanisms in the treatment of central nervous system cancer. Seminars in Pediatric Neurology, 2000, 7, 131-143.	2.0	24
131	Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. , 1998, 78, 196-201.		95
132	Suppression of CD44 expression decreases migration and invasion of human glioma cells. International Journal of Cancer, 1996, 66, 255-260.	5.1	66